As a life sciences company doing business in the United States, it is important to not only be aware of the latest trends in the industry, but also any potential (and actual) developments in the law that may impact the business. With the recent emergence of China as a noteworthy contender in the biotech space, the proposed BIOSECURE Act (H.R. 7085) received a lot of attention last year. This proposed legislation sought to place restrictions on companies that contracted with a “biotechnology company of concern,” or used such biotechnology equipment or services. The bill explicitly identified five Chinese “biotechnology companies of concern”: “Beijing Genome Institute (BGI), MGI Tech Solutions (MGI), Complete Genomics, WuXi AppTec, and WuXi Biologics, and any subsidiary, parent affiliate or successor of such entities.” If passed, the Act would prohibit U.S. federal funding (for example, loans, grants, and contracts) in connection with obtaining or procuring biotechnology equipment or services produced or provided by a “biotechnology company of concern.”

Click here to read the full article written by Sean Kim and Simone Park published on pages 43-45 in the 2025 BIO KOREA International Convention conference preview.